口腔颌面颈部Castleman病：6例临床病例报告和文献复习

›› 2019, Vol. 39 ›› Issue (3): 246-249.

口腔颌面颈部Castleman病：6例临床病例报告和文献复习

何小桐¹,王琼¹,吴亚平¹,王东苗²,王琰玲¹,程杰¹

1. 南京医科大学附属口腔医院
2. 江苏省口腔疾病研究重点实验室;南京医科大学附属口腔医院口腔颌面外科

收稿日期:2017-10-27 修回日期:2017-12-09 出版日期:2019-03-28 发布日期:2019-03-22
通讯作者: 程杰 E-mail:leonardo_cheng@163.com

Castleman’s disease in oral maxillofacial and neck region: report of six new cases and literature review

Received:2017-10-27 Revised:2017-12-09 Online:2019-03-28 Published:2019-03-22

摘要/Abstract

摘要： 目的　探讨口腔颌面颈部较为罕见的淋巴组织增生疾病Castleman’s Disease（CD）的临床病理特点、诊断及治疗预后。方法:收集2007年至2017年间就诊于南京医科大学附属口腔医院、病理确诊为口腔颌面颈部CD的患者，分析相关临床病理特征和随访资料。结果：本文共收集了6例口腔颌面颈部CD患者，临床表现均为单个渐大无痛性肿物；所有患者均行手术切除治疗；术后病理诊断均为透明血管型CD (hyaline-vascular CD, HVCD)；随访2月至9年余，均无肿物复发。结论:口腔颌面颈部Castleman病较为罕见，确诊依赖病理，临床上以单中心型CD（unicentric CD, UCD）多见，治疗主要是手术切除，总体预后良好。

关键词: Castleman病, 头颈部, 临床表现, 治疗, 预后

Abstract: Objective　To summarize the clinical, pathological characteristics and treatment of Castleman’s disease (CD) in oral, maxillofacial and neck region. Methods　The CD cases in oral maxillofacial and neck region treated in Affiliated Stomatological Hospital, Nanjing Medical University from 2007 to 2017 were identified. The relevant clinicopathological and follow-up data were collected and presented. Results　Six cases of CD were identified with the histopathological subtype as hyaline-vascular type. Surgical resection of these masses was performed in all cases. No evidence of disease recurrence was found during the follow-up ranging from 2 months to 9 years. Conclusions　Castleman disease rarely occurs in oral, maxillofacial and neck region and its diagnosis relies on pathological examination. Surgical resection is a primary treatment with favorable prognosis.

Key words: Castleman’s Disease, head and neck, clinical presentation, diagnosis, Prognosis

中图分类号:

R739.81

何小桐王琼吴亚平王东苗王琰玲程杰. 口腔颌面颈部Castleman病：6例临床病例报告和文献复习[J]. , 2019, 39(3): 246-249.

参考文献

[1]Talat N, Belgaumkar AP, Schulte KM.Surgery in Castleman's disease: a systematic review of 404 published cases[J].Ann Surg, 2012, 255(4):677-684
[2]CASTLEMAN B, IVERSON L, MENENDEZ VP.Localized mediastinal lymphnode hyperplasia resembling thymoma[J].Cancer, 1956, 9(4):822-830
[3]Chan KL, Lade S, Prince HM, et al.Update and new approaches in the treatment of Castleman disease[J]. J Blood Med, 2016, 7: 145-158.
[4]Lin CY, Chang YL.Castleman's disease in the head and neck region: Meta-analysis of reported cases in Taiwan and literature review[J].Taiwan yi zhi, 2010, 109(12):913-920
[5]张路, 李剑.病发病机制研究进展[J].中国医学科学院学报, 2016, 38(1):118-121
[6]Leger-Ravet MB, Peuchmaur M, Devergne O, et al.Interleukin-6 gene expression in Castleman's disease[J].Blood, 1991, 78(11):2923-2930
[7]Nishimoto N, Terao K, Mima T, et al.Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody,tocilizumab,in patients with rheumatoid arthritis and Castleman disease[J].Blood, 2008, 112(10):3959-3964
[8]Turcotte LM, Correll CK, Reed RC, et al.Sustained remission of severe Multicentric Castleman disease following multiagent chemotherapy and tocilizumab maintenance[J].Pediatr Blood Cancer, 2014, 61(4):737-739
[9]Dupin N, Diss TL, Kellam P, et al.HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma[J].Blood, 2000, 95(4):1406-1412
[10]de Vries I A, van Acht M M, Demeyere T B, et al.Neoadjuvant radiotherapy of primary irresectable unicentric Castleman's disease: a case report and review of the literature[J].Radiation Oncology, 2010, 5(1):7-
[11]Fajgenbaum DC, van Rhee F, Nabel CS.HHV-8-negative,idiopathic multicentric Castleman disease: novel insights into biology,pathogenesis,and therapy[J].Blood, 2014, 123(19):2924-2933
[12]Liu AY, Nabel CS, Finkelman BS, et al.Idiopathic multicentric Castleman's disease: a systematic literature review[J].Lancet Haematol, 2016, 3(4):e163-e175
[13]Bollig C, Moon S, Sujoy V, et al.Castleman disease of the parotid in childhood: a case report[J].Am J Otolaryngol, 2014, 35(4):517-519
[14]Wang HW, Pittaluga S, Jaffe ES.Multicentric Castleman disease: Where are we now[J].Semin Diagn Pathol, 2016, 33(5):294-306
[15]Cronin DM, Warnke RA.Castleman disease: an update on classification and the spectrum of associated lesions[J].Adv Anat Pathol, 2009, 16(4):236-246
[16]Lai CH, Tsai JW, Lin JN, et al.Plasma-cell type Castleman's disease of the neck and lymphocyte-depletion Hodgkin lymphoma associated with intestinal intussusception in an AIDS patient[J].Wei mian yu gan ran za zhi, 2013, 46(3):234-236
[17]Inada K, Hamazaki M.Localized Mediastinal Lymph-Node Hyperplasia Resembling Thymoma[J].Annals of Surgery, 1958, 147(3):409-413
[18]Al Kadah B, Popov HH, Schick B, et al.Cervical lymphadenopathy: study of 251 patients[J].Eur Arch Otorhinolaryngol, 2015, 272(3):745-752
[19]Linkhorn H, van der Meer G, Gruber M, et al.Castleman' s disease: An unusually young presentation resulting in delayed diagnosis of a neck mass[J]. Int J Pediatr Otorhinolaryngol, 2016, 86: 90-92.
[20]Thakral B, Zhou J, Medeiros LJ.Extranodal hematopoietic neoplasms and mimics in the head and neck: an update[J].Hum Pathol, 2015, 46(8):1079-1100
[21]Chronowski GM, Ha CS, Wilder RB, et al.Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy[J].Cancer, 2001, 92(3):670-676
[22]Li YM, Liu PH, Zhang YH, et al.Radiotherapy of unicentric mediastinal Castleman's disease[J].Chin J Cancer, 2011, 30(5):351-356
[23]江倩, 桂婷, 倪小兵, 等.头颈部多中心型病例[J].临床口腔医学杂志, 2014, 30(1):24-26
[24]van Rhee F, Casper C, Voorhees PM, et al.A phase 2,open-label,multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease[J].Oncotarget, 2015, 6(30):30408-30419